Bristol-Myers and the activist investors at Starboard have had their say on the pending $74 billion Celgene merger. Some influential voices—namely proxy advisors—have yet to weigh in, though, and their verdicts could sway undecided shareholders ahead of the crucial April 12 vote.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,